Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Blood Transfus ; 9(4): 430-5, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21627919

RESUMO

BACKGROUND: Blood transfusion is a complex activity. Some of the components of this activity are implementation of standard procedures, evaluation of appropriateness of the blood use, methods for bedside identification of patients and the release of blood in emergencies, during out-of-routine hours and from hospitals lacking a Blood Centre. An overview about how these issues are managed in Italy could be of interest. MATERIALS AND METHODS: A survey dealing with some issues regarding blood release was performed, using a questionnaire sent to 278 Italian Blood Centres. RESULTS: Out of the 278 Centres, 179 (64%) returned the questionnaire. The geographic distribution of the Centres that responded (80 in the north, 46 in the centre and 53 in the south of Italy) offers a good picture of the Italian reality. Globally there seems to be a relatively uniform application of procedures and guidelines, of methods to identify patients, and of evaluating transfusion appropriateness. The systems used to deal with emergency blood release and blood release in non-routine conditions are more variable. The use of technological resources seems to be disappointingly low. DISCUSSION: Although many aspects of the blood transfusion process should be improved, the picture that emerged from the survey seems to show, on the whole, a fair quality of blood transfusion practice in Italian Blood Centres.


Assuntos
Transfusão de Sangue/normas , Humanos , Itália , Estudos Prospectivos , Estudos Retrospectivos , Inquéritos e Questionários
2.
Hepatogastroenterology ; 53(72): 919-23, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17153453

RESUMO

BACKGROUND/AIMS: Lamivudine has been shown to benefit patients with anti-HBe/HBV-DNA-positive chronic hepatitis B. The aim of the study was to evaluate factors influencing outcome of lamivudine therapy during two years of post-treatment follow-up in a prospective clinical trial. METHODOLOGY: Thirty-one consecutive patients, submitted to liver biopsy, were treated with lamivudine at 100mg/daily for twelve months and followed-up for twenty-four months. The patients were never treated before with interferon or stopped at least six months before starting lamivudine. ALT was measured monthly and HBV-DNA every three months. RESULTS: At the end of therapy 25 (81%) patients had both biochemical and virological response; 2 (6%) patients showed persistent viremia and 4 (13%) patients developed viral resistance during treatment. Twenty-three (92%) out of 25 responders relapsed during the follow-up; over 50% of all cases relapsed within 6 months. The relapse is related to higher HBV-DNA baseline levels. At relapse, 4/23 (17%) patients had symptomatic acute hepatitis. CONCLUSIONS: Lamivudine is associated with the risk of developing viral mutants and, after therapy discontinuation, to high rate of relapse. In relapsing patients severe acute recurrence of hepatitis B may occur. Decisions about lamivudine monotherapy should take into account the limited long-term efficacy, effects of relapse, costs and predictive factors for response.


Assuntos
Alanina Transaminase/sangue , DNA Viral/sangue , Antígenos E da Hepatite B/sangue , Hepatite B Crônica/tratamento farmacológico , Lamivudina/uso terapêutico , Inibidores da Transcriptase Reversa/uso terapêutico , Adolescente , Adulto , Feminino , Vírus da Hepatite B/efeitos dos fármacos , Vírus da Hepatite B/genética , Vírus da Hepatite B/isolamento & purificação , Humanos , Lamivudina/efeitos adversos , Masculino , Pessoa de Meia-Idade , Recidiva , Inibidores da Transcriptase Reversa/efeitos adversos , Resultado do Tratamento , Viremia/virologia
3.
Transfus Apher Sci ; 34(1): 11-4, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16427809

RESUMO

HEMOLYTIC UREMIC SYNDROME POST-PARTUM: We describe a case of a 37-year-old woman admitted for severe renal failure to our hospital immediately after the delivery by caesarean section of twins. She had anuria, anemia, and moderate thrombocytopenia. A diagnosis of hemolytic-uremic syndrome was made. Plasma exchange was started, substitution was performed with fresh frozen plasma and eight consecutive plasmapheresis sessions were given. She received hydrocortisone and ACE inhibitors. After about fifteen days from the beginning of the illness, signs of active haemolysis disappeared and renal function was partially recovered. A genetic study demonstrated the absence of HF1 and MCP mutations but a polymorphic variant of the HF1 gene (C-257T promoter region). This polymorphism is strongly associated with non-diarrhoea-HUS (D-HUS). Post-partum HUS is quite a rare syndrome and has a poor outcome; however prompt diagnosis and efficacious therapy could save lives without clinical consequences. The excellent outcome of this patient seems to corroborate this concept.


Assuntos
Síndrome Hemolítico-Urêmica/diagnóstico , Pré-Eclâmpsia/terapia , Adulto , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Fator H do Complemento/genética , Fator H do Complemento/metabolismo , Feminino , Hemólise , Humanos , Hidrocortisona , Proteína Cofatora de Membrana/genética , Troca Plasmática/métodos , Plasmaferese , Polimorfismo Genético , Período Pós-Parto , Gravidez , Regiões Promotoras Genéticas , Insuficiência Renal/terapia , Trombose
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA